2005
DOI: 10.1016/j.blre.2005.01.004
|View full text |Cite
|
Sign up to set email alerts
|

Myelodysplasic syndromes: A comprehensive review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
52
0
9

Year Published

2007
2007
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 76 publications
(61 citation statements)
references
References 229 publications
0
52
0
9
Order By: Relevance
“…1,3,30,31 In this model an abnormal hematopoietic clone would interact with an altered BM microenvironment. Newer knowledge is appearing showing new molecular alterations involved in MDS development, recently it has been shown that ribosomal proteins could participate in some MDSs development such as 5qÀ syndrome.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…1,3,30,31 In this model an abnormal hematopoietic clone would interact with an altered BM microenvironment. Newer knowledge is appearing showing new molecular alterations involved in MDS development, recently it has been shown that ribosomal proteins could participate in some MDSs development such as 5qÀ syndrome.…”
Section: Discussionmentioning
confidence: 99%
“…1 MDS is the result of a multi-step sequence of genomic injures to Bone Marrow (BM) stem cell. Although clonal chromosomal abnormalities are detected in 40-70% of de novo MDS, and in 95% of therapy-related MDS, there is no cytogenetic abnormality specific for MDS.…”
Section: Introductionmentioning
confidence: 99%
“…1 Symptoms in MDS are caused by insufficient numbers of circulating erythrocytes, leukocytes and/or platelets. Approximately 50% of MDS patients have cytogenetic abnormalities in their malignant clone.…”
Section: Introductionmentioning
confidence: 99%
“…Si bien de forma excepcional, la inmunosupresión secundaria a corticoterapia prolongada puede ser responsable de la reactivación y diseminación de un foco tuberculoso (20,21). A esta circunstancia habría que aña-dir en nuestro paciente el padecimiento de una hemopatía maligna, con un componente de mielodisplasia que predispone a padecer complicaciones infecciosas (22). Finalmente, destacamos la buena respuesta al tratamiento antituberculoso y la buena evolución de nuestro paciente, teniendo en cuenta que la mortalidad descrita para la tuberculosis peritoneal, sobre todo asociada a la cirugía, se sitúan entre un 20 y un 30% según las series (11,13,23).…”
Section: Discussionunclassified